MedImmune bolsters autoimmune disease research
This article was originally published in Scrip
Executive Summary
MedImmunehas boosted its autoimmune disease programme through an agreement with SBI Biotechfor the anti-ILT7 protein, which has potential as a systemic lupus erythematosus treatment. The biologics unit of AstraZenecawill research, develop and commercialise products that target the ILT7 protein.